BACKGROUND: Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma. METHODS: A randomized, double-blind, phase 2 trial was conducted comparing placebo with bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks; the time to progression of disease and the response rate were primary end points. Crossover from placebo to antibody treatment was allowed, and survival was a secondary end point. RESULTS:Minimal toxic effects were seen, with hypertension and asymptomatic proteinuria predominating. The trial was stopped after the interim analysis met the criteria for early stopping. With 116 patients randomly assigned to treatment groups (40 to placebo, 37 to low-dose antibody, and 39 to high-dose antibody), there was a significant prolongation of the time to progression of disease in the high-dose--antibody group as compared with the placebo group (hazard ratio, 2.55; P<0.001). There was a small difference, of borderline significance, between the time to progression of disease in the low-dose--antibody group and that in the placebo group (hazard ratio, 1.26; P=0.053). The probability of being progression-free for patients given high-dose antibody, low-dose--antibody, and placebo was 64 percent, 39 percent, and 20 percent, respectively, at four months and 30 percent, 14 percent, and 5 percent at eight months. At the last analysis, there were no significant differences in overall survival between groups (P>0.20 for all comparisons). CONCLUSIONS:Bevacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer. Copyright 2003 Massachusetts Medical Society
RCT Entities:
BACKGROUND: Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma. METHODS: A randomized, double-blind, phase 2 trial was conducted comparing placebo with bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks; the time to progression of disease and the response rate were primary end points. Crossover from placebo to antibody treatment was allowed, and survival was a secondary end point. RESULTS: Minimal toxic effects were seen, with hypertension and asymptomatic proteinuria predominating. The trial was stopped after the interim analysis met the criteria for early stopping. With 116 patients randomly assigned to treatment groups (40 to placebo, 37 to low-dose antibody, and 39 to high-dose antibody), there was a significant prolongation of the time to progression of disease in the high-dose--antibody group as compared with the placebo group (hazard ratio, 2.55; P<0.001). There was a small difference, of borderline significance, between the time to progression of disease in the low-dose--antibody group and that in the placebo group (hazard ratio, 1.26; P=0.053). The probability of being progression-free for patients given high-dose antibody, low-dose--antibody, and placebo was 64 percent, 39 percent, and 20 percent, respectively, at four months and 30 percent, 14 percent, and 5 percent at eight months. At the last analysis, there were no significant differences in overall survival between groups (P>0.20 for all comparisons). CONCLUSIONS:Bevacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer. Copyright 2003 Massachusetts Medical Society
Authors: M S Gordon; K Margolin; M Talpaz; G W Sledge; E Holmgren; R Benjamin; S Stalter; S Shak; D Adelman Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe Journal: Nature Date: 1999-05-20 Impact factor: 49.962
Authors: Kevin J Turner; John W Moore; Adam Jones; Claire F Taylor; Darren Cuthbert-Heavens; Cheng Han; Russell D Leek; Kevin C Gatter; Patrick H Maxwell; Peter J Ratcliffe; David Cranston; Adrian L Harris Journal: Cancer Res Date: 2002-05-15 Impact factor: 12.701
Authors: C Mundhenke; J P Thomas; G Wilding; F T Lee; F Kelzc; R Chappell; R Neider; L A Sebree; A Friedl Journal: Clin Cancer Res Date: 2001-11 Impact factor: 12.531
Authors: Mircea Ivan; Thomas Haberberger; David C Gervasi; Kristen S Michelson; Volkmar Günzler; Keiichi Kondo; Haifeng Yang; Irina Sorokina; Ronald C Conaway; Joan W Conaway; William G Kaelin Journal: Proc Natl Acad Sci U S A Date: 2002-09-26 Impact factor: 11.205
Authors: Kristan D Guenterberg; Valerie P Grignol; Kiran V Relekar; Kimberly A Varker; Helen X Chen; Kari L Kendra; Thomas E Olencki; William E Carson Journal: Am J Clin Oncol Date: 2011-02 Impact factor: 2.339
Authors: Gerald S Falchook; Jennifer J Wheler; Aung Naing; Sarina A Piha-Paul; Siqing Fu; Apostolia M Tsimberidou; David S Hong; Filip Janku; Ralph Zinner; Yunfang Jiang; Mei Huang; Quan Lin; Kristin Parkhurst; Razelle Kurzrock Journal: Invest New Drugs Date: 2014-11-04 Impact factor: 3.850
Authors: Roberto Ballarin; Mario Spaggiari; Nicola Cautero; Nicola De Ruvo; Roberto Montalti; Cristina Longo; Anna Pecchi; Patrizia Giacobazzi; Giuseppina De Marco; Giuseppe D'Amico; Giorgio Enrico Gerunda; Fabrizio Di Benedetto Journal: World J Gastroenterol Date: 2011-11-21 Impact factor: 5.742
Authors: Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Jennifer M Roth; Abebe Akalu; Anat Zelmanovich; Desiree Policarpio; Bruce Ng; Shannon MacDonald; Silvia Formenti; Leonard Liebes; Peter C Brooks Journal: Am J Pathol Date: 2005-03 Impact factor: 4.307
Authors: Richard W Joseph; Mansi Parasramka; Jeanette E Eckel-Passow; Dan Serie; Kevin Wu; Liuyan Jiang; Krishna Kalari; R Houston Thompson; Thai Huu Ho; Erik P Castle; John Cheville; Eugene D Kwon; E Aubrey Thompson; Alexander Parker Journal: Cancer Immunol Res Date: 2013-08-29 Impact factor: 11.151